We sought to elucidate the role of imbalanced mitochondrial dynamics in calcium oxalate nephrolithiasis and the ameliorative effect of PPARγ agonist treatment on mitochondrial damage in TECs. The gene discussed is PPARG; the disease is nephrolithiasis susceptibility caused by SLC26A1.